We believe that, with the further development of fundamental research, we are looking forward to an increasing application prospect of tyrosine kinase inhibitors in clinical practice.
Acknowledgements The authors wish to thank Dr. Jan Zhang for his kind review of the manuscript, Dr. Feng Wei TPX-0005 cost for their expert technical assistance, Ms. Min-Yu Wang for her excellent laboratory management. This work was supported by a grant from the Ministry of Civil Affair, China (18). References 1. Masui H, Kawamoto T, Sato JD: Growth inhibition of human tumor cells in athymicmice by anti-Tideglusib cost Epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984, 44: 1002–1007.PubMed 2. Yaish P, Gazit A, Gilon C: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988, 242: 933–935.CrossRefPubMed 3. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4: 361–370.CrossRefPubMed 4. Jose B: Epidermal growth factor receptor pathway inhibitors. Update on cancer therapeutics 2006, 1: 299–310.CrossRef 5. Fortunato C, Giampaolo T: EGFR Antagonists in
Cancer Treatment. Oligomycin A N Engl J Med 2008, 358: 1160–1174.CrossRef 6. Fortunato C, Giampaolo T: Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor. Clinical Cancer Res 2001, 7: 2958–2970. 7. Zhu ZP: Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin 2007, 28: 1476–1493.CrossRefPubMed 8. Harari PM: Epidermal
growth factor receptor inhibition strategies of in oncology. Endocr Relat Cancer 2004, 11: 689–708.CrossRefPubMed 9. Olivier D, Alexandre, Gerard M: EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors Similarities and differences. Crit Rev Oncol Hemato 2007, 62: 53–61.CrossRef 10. Kris MG, Natale RB, Herbst RS: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290: 2149–2158.CrossRefPubMed 11. Fukuoka M, Yano S, Giaccone G: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial)[corrected]. J Clin Oncol 2003, 21: 2237–2246.CrossRefPubMed 12. Bonner JA, Harari PM, Giralt J: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354: 567–578.CrossRefPubMed 13. Cunningham D, Humblet Y, Siena S: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351: 337–345.CrossRefPubMed 14. Haas-Kogan DA, Prados MD, Tihan T: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97: 880–887.CrossRefPubMed 15.